» Authors » Havard E Danielsen

Havard E Danielsen

Explore the profile of Havard E Danielsen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 66
Citations 1382
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Kleppe A, Lindemann K, Kildal W, Tobin K, Pradhan M, Vlatkovic L, et al.
Gynecol Oncol . 2024 Nov; 192():80-88. PMID: 39549540
Introduction: The role of molecular classification and L1CAM in high-risk endometrial cancer is uncertain. We aimed to determine the association of molecular profiling and L1CAM with patterns of relapse and...
2.
Kildal W, Cyll K, Kalsnes J, Islam R, Julbo F, Pradhan M, et al.
Heliyon . 2024 Jul; 10(13):e32529. PMID: 39040241
We aimed to develop deep learning (DL) models to detect protein expression in immunohistochemically (IHC) stained tissue-sections, and to compare their accuracy and performance with manually scored clinically relevant proteins...
3.
Cyll K, Haug E, Pradhan M, Vlatkovic L, Carlsen B, Loffeler S, et al.
Br J Cancer . 2024 Jul; 131(5):895-904. PMID: 38961192
Background: Current risk stratification tools for prostate cancer patients under active surveillance (AS) may inadequately identify those needing treatment. We investigated DNA ploidy and PTEN as potential biomarkers to predict...
4.
Lindemann K, Kildal W, Kleppe A, Tobin K, Pradhan M, Isaksen M, et al.
Eur J Cancer . 2024 Feb; 200:113584. PMID: 38330767
Introduction: The role of molecular classification in patients with low/intermediate risk endometrial cancer (EC) is uncertain. Higher precision in diagnostics will inform the unsettled debate on optimal adjuvant treatment. We...
5.
Frei A, McGuigan A, Sinha R, Jabbar F, Gneo L, Tomasevic T, et al.
Lancet Oncol . 2024 Feb; 25(2):198-211. PMID: 38301689
Background: Tumour-infiltrating CD8 cytotoxic T cells confer favourable prognosis in colorectal cancer. The added prognostic value of other infiltrating immune cells is unclear and so we sought to investigate their...
6.
Yang L, Yang J, Kleppe A, Danielsen H, Kerr D
Nat Rev Clin Oncol . 2023 Nov; 21(1):67-79. PMID: 38001356
The current standard-of-care adjuvant treatment for patients with colorectal cancer (CRC) comprises a fluoropyrimidine (5-fluorouracil or capecitabine) as a single agent or in combination with oxaliplatin, for either 3 or...
7.
Frei A, McGuigan A, Sinha R, Glaire M, Jabbar F, Gneo L, et al.
J Pathol Clin Res . 2023 Sep; 9(6):449-463. PMID: 37697694
Multiplex immunofluorescence (mIF) imaging can provide comprehensive quantitative and spatial information for multiple immune markers for tumour immunoprofiling. However, application at scale to clinical trial samples sourced from multiple institutions...
8.
Kleppe A, Skrede O, de Raedt S, Hveem T, Askautrud H, Jacobsen J, et al.
Lancet Oncol . 2022 Aug; 23(9):1221-1232. PMID: 35964620
Background: The DoMore-v1-CRC marker was recently developed using deep learning and conventional haematoxylin and eosin-stained tissue sections, and was observed to outperform established molecular and morphological markers of patient outcome...
9.
Marshall J, Peshkin B, Yoshino T, Vowinckel J, Danielsen H, Melino G, et al.
Oncologist . 2022 Apr; 27(4):272-284. PMID: 35380712
Within the last decade, the science of molecular testing has evolved from single gene and single protein analysis to broad molecular profiling as a standard of care, quickly transitioning from...
10.
Cyll K, Kleppe A, Kalsnes J, Vlatkovic L, Pradhan M, Kildal W, et al.
Cancers (Basel) . 2021 Sep; 13(17). PMID: 34503100
Machine learning (ML) is expected to improve biomarker assessment. Using convolution neural networks, we developed a fully-automated method for assessing PTEN protein status in immunohistochemically-stained slides using a radical prostatectomy...